Related Experiment Videos
ESOT update on immunosuppressive substances in clinical development or use 1995
1Division of Nephrology, Kantonsspital Basel, Switzerland.
Summary
The European Society for Organ Transplantation (ESOT) surveyed companies on new immunosuppressive drugs. 16 of 31 companies responded, with 11 detailing 16 novel immunosuppressive substances.
Area of Science:
- Immunosuppression research
- Pharmaceutical development
- Transplantation medicine
Background:
- The European Society for Organ Transplantation (ESOT) Council initiated an inquiry to update its members.
- Keeping abreast of novel immunosuppressive agents is crucial in transplantation.
Purpose of the Study:
- To survey pharmaceutical companies regarding the development of new immunosuppressive substances and antibodies.
- To inform ESOT members about the current landscape of novel immunosuppressive agents.
Main Methods:
- A questionnaire was sent to 31 pharmaceutical companies.
- Responses were collected regarding the development status of new immunosuppressive agents.
- Data from responding companies were analyzed.
Main Results:
- Sixteen companies responded to the inquiry.
- Eleven companies provided information on 16 new immunosuppressive substances.
- Five companies reported no new immunosuppressive agent development.
- Fifteen companies did not respond.
Conclusions:
- A significant number of new immunosuppressive substances are under development by pharmaceutical companies.
- Further updates are needed to fully map the immunosuppressive drug pipeline.